POZ Community Forums

Meds, Mind, Body & Benefits => Research News & Studies => Topic started by: Jim Allen on July 25, 2016, 07:30:58 am

Title: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Jim Allen on July 25, 2016, 07:30:58 am
I thought this was an interesting read on dual therapy.

Personally I would not mind being part of this study if the chance did come along. Taking just the dolutegravir plus lamivudine versus the standard regimen of dolutegravir plus tenofovir/emtricitabine being offered.

http://www.aidsmap.com/page/3074283/
"We need to wait and see," Dr Cahn cautioned. "Donít do this at home until we have the results."

"In this pilot, proof of concept study, dual therapy with dolutegravir plus lamivudine induced rapid virologic suppression with a favourable safety/tolerability profile in HIV-1 infected, treatment-naive individuals," the researchers concluded. "If confirmed in a well powered randomized clinical trial, this two-drug regimen might be considered as a simple, potent, well tolerated and potentially cheap strategy for HIV treatment initiation."

Dr Cahn said more data from larger trials is needed to determine if dual therapy is a safe and effective strategy.


Next: https://clinicaltrials.gov/show/NCT02831673
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: gorka on July 26, 2016, 11:41:56 am
how does one find locations participating?   I only see the following

Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02831673
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Jim Allen on July 26, 2016, 12:51:01 pm
Well under contacts it has: (Don't hold your breath about joining)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02831673

Contacts

Contact: US GSK Clinical Trials Call Center   877-379-3718   GSKClinicalSupportHD@gsk.com   
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: awakening on July 26, 2016, 02:20:40 pm
Thanks for posting this Jim.

The study is only for ARV therapy naive patients (less than 10 days on ART after testing positive). The combo being compared is Triumeq minus the Abacavir, the one ingredient associated with potentially more side effects than the other two.
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Jim Allen on July 26, 2016, 02:48:34 pm
Hence I said to gorka, don't hold your breath.  ;)

Still if it was ever offered to a wider scope of people I would not mind trying, sounds very interesting.

Jim
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: connor on September 15, 2016, 12:50:02 am
I've been on dual therapy with Dolutegravir and Lumivudine since around Christmas 2015. I had hypersensitivity to Abacavir component of Triumeq within a week of starting Triumeq. I was tested okay to go on Abacavir bit I am one of the few people who became hypersensitive. It was a horrible experience. My consultant doctor decided to take Abacavir out of the equation and so I've been left on Dolutegravir and Lumivudine with good results. I've no side effects compared to previous regimes which is why I changed meds so often as you can see in my signature underneath. I have with or without food.
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Jim Allen on September 15, 2016, 02:25:38 am
Sorry to hear you where hypersensitive to Abacavir, but glad to hear your treatment is working well.

Jim
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: vrsan on September 16, 2016, 05:13:13 am
Interesting read, thank you! As i'm already on 3TC+DTG+TDF, i hope this study will find that dual therapy works safely, and works for people already on treatment as well. I really wouldn't mind getting rid for Tenofovir DF :)
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: terrymoore on September 19, 2016, 04:01:34 am
What would be the advantage of a Dual therapy as opposed to the triple? Why is it better to take 2 drugs and not 3?
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Ptrk3 on September 19, 2016, 05:26:06 am
I believe that some of the advantages may be cost (elimination of one drug should, theoretically, make a retroviral cheaper, at least after a while), pill burden (i.e., the lesser chance of side effects since one drug would be eliminated), access (perhaps, more people worldwide would be able to be medicated) and pharmaceutical production (simpler way to make life-sustaining retroviral medication). 

Why take three drugs when two will do?
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: awakening on November 03, 2016, 02:32:34 am
Good results from recent dual-therapy studies:

https://www.poz.com/article/two-hiv-drugs-can-good-three (https://www.poz.com/article/two-hiv-drugs-can-good-three)

Quote
HIV-positive individuals who switched from a standard three-drug antiretroviral (ARV) regimen to a two-drug combination of a boosted protease inhibitor and Epivir (lamivudine) did well in a recent trial, aidsmap reports.
Title: Re: GEMINI trial - study, dual therapy with dolutegravir plus lamivudine
Post by: Jim Allen on November 03, 2016, 03:01:04 am
Yeah, this was not bad result, very promising indeed. I still have to read in detail but it's looking good for further development/study. 

"After 48 weeks of treatment, a respective 89.5 percent and 79.7 percent of those in the dual and triple therapy arms had not failed treatment"

For the ongoing GEMINI 1 and 2 study it will be intressting to see publications once conculded at 48 weeks and than also the 148 weeks total from the study to see the long-term efficiency and the safety.

Jim


https://www.poz.com/article/viiv-begins-phase-iii-trial-twodrug-hiv-regimen